NCT07731880 Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers
| NCT ID | NCT07731880 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fred Hutchinson Cancer Center |
| Condition | Malignant Female Reproductive System Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-11 |
| Primary Completion | 2029-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2026-11 with a primary completion date of 2029-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is being done to determine how easy it is to use standard of care (SOC) surgical resections or biopsy for SmartMatch analysis to determine treatment options in advanced gynecological malignancies.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed rare gynecologic malignancy, including but not limited to those listed * Metastatic or unresectable disease, OR disease for which additional systemic therapy is indicated * Fresh tumor tissue available from a SOC surgical procedure or biopsy that in the judgment of the treating team will yield adequate viable tumor for SmartMatch analysis * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Adequate organ function to receive systemic therapy as determined by the treating oncologist (protocol does not specify thresholds because therapy is not mandated) * Ability to understand and willingness to sign informed consent * Willingness to allow data abstraction from the electronic health record for study endpoints Exclusion Criteria: * Lack of tumor tissue suitable for SmartMatch analysis * Purely borderline tumors or benign ovarian/uterine neoplasms * Any condition that, in the opinion of the treating oncologist or PI, would interfere with receiving systemic therapy * Inability to provide informed consent or comply with study procedures
Contact & Investigator
Kalyan Banda, MD
PRINCIPAL INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Frequently Asked Questions
Who can join the NCT07731880 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Malignant Female Reproductive System Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07731880 currently recruiting?
Yes, NCT07731880 is actively recruiting participants. Contact the research team at bkalyan@uw.edu for enrollment information.
Where is the NCT07731880 trial being conducted?
This trial is being conducted at Seattle, United States.
Who is sponsoring the NCT07731880 clinical trial?
NCT07731880 is sponsored by Fred Hutchinson Cancer Center. The principal investigator is Kalyan Banda, MD at Fred Hutch/University of Washington Cancer Consortium. The trial plans to enroll 30 participants.